Updated product label allows home administration of omacetaxine mepesuccinate

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

BMC cancer·2024

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

BMC cancer·2024

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

BMC cancer·2024

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

BMC cancer·2024

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

BMC cancer·2024

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.

Investigational new drugs·2024

Global management of drug-drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist.

The oncologist·2026

Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023).

The oncologist·2026

Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.

The oncologist·2026

The insufficient publication of early-phase clinical trials in oncology.

The oncologist·2026

A Secret-Shopper Study Evaluating Logistic Barriers to Care Among Young Adults with Acute Lymphoblastic Leukemia.

The oncologist·2026

Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC Chemotherapy.

The oncologist·2026

Advances and Applications of 3D Printing and Additive Manufacturing: Current Progress, Challenges, and Future Outlook.

Materials (Basel, Switzerland)·2026

Modified Plasmids and Inverted Terminal Repeats Enhance Adeno-Associated Virus Production and Performance.

International journal of molecular sciences·2026

What Makes an AI Persuasive? The Interaction Effect of AI Shopping Assistants and Algorithmic Recommendation Cues on Consumers' Organic Food Purchase Intention.

Foods (Basel, Switzerland)·2026

Host determinants of exo-rAAV production revealed by extended gene expression analysis in HEK293 cells.

Molecular therapy. Advances·2026

Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency.

Microorganisms·2026

Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing.

Pharmaceutics·2026

Related Experiment Videos

Updated product label allows home administration of omacetaxine mepesuccinate

Related Concept Videos

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.

Global management of drug-drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist.

Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023).

Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.

The insufficient publication of early-phase clinical trials in oncology.

A Secret-Shopper Study Evaluating Logistic Barriers to Care Among Young Adults with Acute Lymphoblastic Leukemia.

Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC Chemotherapy.

Advances and Applications of 3D Printing and Additive Manufacturing: Current Progress, Challenges, and Future Outlook.

Modified Plasmids and Inverted Terminal Repeats Enhance Adeno-Associated Virus Production and Performance.

What Makes an AI Persuasive? The Interaction Effect of AI Shopping Assistants and Algorithmic Recommendation Cues on Consumers' Organic Food Purchase Intention.

Host determinants of exo-rAAV production revealed by extended gene expression analysis in HEK293 cells.

Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency.

Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing.

Related Experiment Videos

Updated product label allows home administration of omacetaxine mepesuccinate

Related Concept Videos

Related Articles